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CD58 mutations are common in Hodgkin 
lymphoma cell lines and loss of CD58 
expression in tumor cells occurs in 
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CD58 is involved in immune recognition of tumor cells via binding of the CD2 
receptor expressed on cytotoxic T cells. In diffuse large B cell lymphoma, 
mutations of the CD58 gene are reported to contribute to immune evasion of 
the tumor cells. We previously showed CD58 mutations in three Hodgkin 
lymphoma (HL) cell lines by whole exome sequencing. In this study, we 
confirmed the mutations by Sanger sequencing at the DNA and RNA level and 
showed low levels or total loss of CD58 mRNA expression in two of the three 
cell lines. CD58 protein expression as determined by flow, western blot and 
IHC was absent in all 3 mutated HL cell lines. In primary tissue samples loss of 
CD58 expression was observed in 11% of the patients who relapse. These 
data suggest that loss of CD58 is a potential immune escape mechanism of HL 
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INTRODUCTION 
Hodgkin lymphoma (HL) accounts for 11% of all malignant lymphomas with 
around 66,000 new cases being diagnosed worldwide in 2012.1 HL is 
characterized by a minority of B-cell derived tumor cells, named Hodgkin Reed-
Sternberg (HRS) cells in classical (c)HL and lymphocyte predominant (LP) cells 
in nodular lymphocyte predominant (NLP) HL. 
 
Our previously reported whole exome sequencing (WES) analysis of seven HL 
cell lines revealed recurrent mutations in multiple immune related genes.2 The 
most common were B2M start codon mutations in L428 and DEV resulting in 
failure to express B2M protein. Without B2M, HLA class I cannot be properly 
assembled and transported to the cell membrane and this loss of HLA class I 
represents an immune escape mechanism for HL tumor cells. In the same 
study, CD58, also known as lymphocyte function-associated antigen-3, was 
shown to be mutated in KMH2 and DEV. CD58, a member of the 
immunoglobulin superfamily, is a heavily glycosylated cell-surface adhesion 
molecule expressed on B cells and T cells.3,4 It is an accessory molecule that 
can provide a co-stimulatory signal to T cells via binding to the CD2 receptor.5 
This interaction is critical for the regulation of effector functions of T cells.4,6 
CD4+ Th2 cells form a main part of the reactive infiltrate in HL and these cells 
form rosettes around the HRS cells.7 The formation of these rosettes was 
shown to be dependent on expression of both CD2 and CD54 on T cells and 
their interaction with CD58 and LFA-1 expressed on L428 cells.8 As the HL 
tumor cells depend on trophic factors and growth stimuli from CD4+ T cells, 
CD58 expression may be necessary for tumor cell survival.9 However, CD58 is 
also involved in immune recognition of tumor cells by cytotoxic T cells (CTL) 
and Natural Killer (NK) cells, via binding to the CD2 receptor.10,11 Thus, loss of 
CD58 molecules may allow HRS cells to escape from immune recognition, 
especially in advanced disease when the tumor cells may have progressed to 
become less dependent on the reactive infiltrate and more immunogenic.12 The 
aim of this study is to analyze CD58 mutations and expression in HL. 
 
MATERIALS AND METHODS 
Cell lines and primary samples 
HL cell lines DEV (NLPHL, cell line developed in house, no data from 
DSMZ&ATCC),13 L428 (nodular sclerosis, DSMZ No ACC 197), L1236 (mixed 
cellularity, DSMZ No ACC 530), KMH2 (mixed cellularity, DSMZ No ACC 8), 
L591 (nodular sclerosis, EBV+, DSMZ No ACC 602) and L540 (nodular 
sclerosis, T cell derived, DSMZ No ACC 72) were cultured in RPMI 1640 




20% (DEV, L540) and 10% (other cell lines) fetal calf serum, 100U/ml 
penicillin/streptomycin and ultraglutamine (Lonza Walkersville) in a 5% CO2 
atmosphere at 37°C. SUPHD1 (lymphocyte depleted subtype, DSMZ No ACC 
574) was cultured in McCoy 5A medium supplemented with 10% fetal calf 
serum. DLBCL cell lines SUDHL4 (DSMZ No ACC 495) was cultured in RPMI 
1640 medium with 10% fetal calf serum. The origin of all cell lines was 
confirmed with STR DNA analysis. Mycoplasma tests consistently showed that 
the cell lines were not contaminated. Tissue samples of 43 HL patients without 
relapse and 53 HL patients with relapse (28 primary tissue samples and 31 
relapse tissue samples) were retrieved from the tissue bank of the Pathology 
Department, University Medical Center Groningen. The study was conducted in 
accordance with the Declaration of Helsinki and the national Code of conduct 
for responsible use of human tissue (FEDERA) guidelines.  
 
DNA and RNA isolation and (Quantitative) RT-PCR  
DNA was isolated by salt-chloroform extraction method and RNA was isolated 
using TRIzol reagent. Complementary DNA (cDNA) was synthesized using 
Superscript II RT (Invitrogen, Carlsbad, USA) and random hexamers. qRT-
PCR was performed with SYBR Green and the Lightcycler 480 (Roche, 
Mannheim, Germany). TBP was used as a housekeeping gene for 
normalization. Primers used for the amplification are listed in Table S2. 
Relative expression levels are expressed as 2-(delta Cp). 
 
Sanger sequencing 
M13 tail containing primer sets were designed to amplify the mutated region at 
the DNA and mRNA level (Table S2). Amplification was performed following 
standard protocols provided by the manufacturer. PCR products were gel 
purified using high pure PCR product purification kit (Roche) and send for 
Sanger sequencing (LGC Genomic, Teddington, UK). 
 
CD58 protein expression 
The expression of CD58 was analyzed by Western blot using a polyclonal anti-
CD58 antibody (1:1000; AF1689, R&D Systems, Minneapolis, USA). As a 
loading control we analyzed expression of GAPDH (1:20000, SC47724, Santa 
Cruz, Heidelberg, Germany). Presence of membranous CD58 on HL cell lines 
was determined on the BD FACS Calibur (BD Biosciences, New Jersey, USA) 
using PE-labelled mouse anti-CD58 antibody (BD555921, BD Biosciences). 
Immunostaining was performed with a polyclonal antibody against CD58 
(AF1689, R&D Systems). After fixation in acetone for 10 minutes, cytospin 
slides were incubated with primary antibody (1:640) at 4°C overnight. Paraffin  
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embedded HL tissue sections were subjected to antigen retrieval in sodium 
citrate buffer (pH 6.0) in a microwave for 15 minutes. Tissue sections were 
incubated with primary antibody (1:80) at 4°C overnight. Positive staining was 
visualized after secondary antibody incubation steps with 3,3'-
Diaminobenzidine (paraffin sections) or 3-amino-9-ethylcarbazole (cytospins). 
The tissues were examined and scored by an experienced hematopathologist 
without prior knowledge of patient outcomes. Positive staining was defined as 
clear presence of membranous staining. Variable weak background staining 
was scored as negative.  
 
Statistical analysis 
Statistical analysis was performed by Mann Whitney U test, Fisher’s exact test 
or Chi square test when appropriate. A p-value less than 0.05 was considered 
to be significant. Statistical analyses were performed with GraphPad Prism 
version 5.0 (GraphPad Software, San Diego, CA, USA) and SPSS statistical 
software (IBM SPSS Statistics 20; IBM Corporation, NY, USA). 
 
RESULTS AND DISCUSSION 
Previously, we reported CD58 mutations in KMH2 and DEV cells, i.e. a splice 
site donor and a stop gain mutation respectively.2 A recent study by Schneider 
et al.12 also reported the CD58 mutation in KMH2 and in addition showed a 
homozygous loss of exons 1 to 3 of the CD58 gene in SUPHD1. Thus, CD58 is 
mutated in three out of seven HL cell lines. We now confirmed the two point 
mutations in KMH2 and DEV by Sanger-sequencing (Figure S1). Moreover we 
confirmed aberrant splicing of the CD58 transcript in KMH2 due to the splice 
site mutation (Figure S1D) as shown by Schneider et al.12 and defined the size 
of the homozygously deleted region in SUPHD1 (Figure S1). As DEV is a cell 
line derived from nodular lymphocyte predominant HL, this finding showed that 
CD58 alterations may also be important in this HL subtype.  
 
In comparison to the HL cell lines with wild type CD58, the mRNA levels were 
low or absent in SUPHD1 and KMH2 cells (Figure 1B). In DEV cells the levels 
were comparable to the other HL cell lines. CD58 membrane expression as 
determined by flow (Figure 1C; Figure S2A) showed lack or low expression in 
all three mutated HL cell lines. These findings were confirmed by Western blot 
(Figure 1D). Immunostaining of the HL cell lines revealed no staining in the 
mutated cell lines, while the other cell lines showed strong staining (Figure 
S2B). These data confirm presence of CD58 gene mutations with concurrent 




Schneider et al.12 identiﬁed heterozygous deletions of CD58 by FICTION 
analysis in 3 out of 13 primary cHL cases. Sequencing analysis of the CD58 
gene on DNA isolated from microdissected HRS cells of 10 cHL cases did not 
reveal any mutations. Reichel et al.14 showed CD58 gene deletions in 2 out of 
10 flow-isolated HRS cells cHL cases. Based on these studies and on our data, 
it is obvious that alterations of the CD58 gene are present in primary HRS cells 
of patients that do experience a relapse, albeit at a low percentage. 
Unfortunately, we were not able to determine presence of mutations in our 
cases with loss of CD58 expression, as we do not have frozen tissue samples 
or cell suspensions available (see below). 
 
In addition to mutations in CD58, various other immune associated genes have 
been shown to be mutated in HL. The CSF2RB gene, encoding the common β 
chain (CD131) shared by the interleukin-3 (IL-3), granulocytic macrophage 
colony-stimulating factor (GM-CSF) and IL-5 receptors, was mutated in 4 out of 
7 HL cell lines.2 STXBP2 required for exocytosis of perforin-containing lytic 
granules was mutated in SUPHD1, L1236 and DEV. Moreover, a bi-allelic 
mutation was reported in STXBP2 in an Epstein-Barr virus positive cHL case 
by Machaczka et al.15 We reported B2M gene mutations affecting the ATG start 
codon in L428 and DEV cells.2 A recent study by Reichel et al.14 reported that 
B2M is the most frequently mutated gene in cHL. Mutations were strongly 
associated with the nodular sclerosis subtype, younger age and better overall 
survival. B2M is essential for proper transport of HLA class I to the cell 
membrane and loss of B2M results in loss of membranous HLA-class I 
expression. 
 
Diffuse large B-cell lymphomas (DLBCL) are also characterized by mutations of 
CD58 and B2M. Loss of CD58 expression is associated with loss of HLA class 
I in DLBCL11 and this co-loss is crucial to avoid triggering of NK cell activation 
by CD58. We showed loss of CD58 protein expression in SUPHD1, DEV and 
KMH2 cells as a consequence of mutations in the CD58 gene in this study. In a 
previous study we showed B2M mutations and loss of HLA class I expression 
in L428 and DEV cells.12 This indicates that L428 cells lost both CD58 and 
B2M, making them vulnerable to NK cell killing, but these cells apparently 
survived, possibly due to the protection from NK cells by the rosetting CD4+ 
Th2 cells.8 So, in contrast to DLBCL, loss of CD58 expression is not restricted 
to HLA class I negative HL cell lines. 
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We next studied CD58 expression in primary tissue samples of 43 HL patients 
without relapse (average follow-up time 6.4 years (0.04 – 16.6 years) (Table 1). 
Consistent with earlier studies,9,16 we showed a strong CD58 staining in HRS 
cells of all HL patients. CD58 expression may be important for HRS cells to 
maintain their capacity as antigen presenting cells and to interact with CD4+ T 
cells that offer growth and survival to the tumor cells.9,16 As HL cell lines are 
derived from refractory or relapsed HL disease with extensive extranodal 
involvement, it might be that loss of CD58 expression is a late event in HL 
progression and may occur when HRS cells want to become independent of 
the T-cell infiltrate for survival. At that point loss of HLA class I and CD58 might 
be a prerequisite for survival of tumor cells as the tumor cells have 
accumulated mutations that can potentially lead to presentation of highly 
immunogenic peptides that can activate cytotoxic T cell responses. We next 
studied CD58 expression in 53 relapsed HL patients. For 22 patients we only 
had primary diagnostic material, for 25 patients we only had relapse tissue and 
for 6 patients we had both (Table S1). In contrast to the consistent strong 
staining pattern of CD58 on HRS cells of patients who did not develop a 
relapse, loss of CD58 staining was observed in 4 out of 28 primary and in 3 out 
of 31 relapse tissue samples. These 7 negative cases were derived from 6 
patients who did relapse. One of the 6 paired cases showed a positive staining 
of HRS cells in the primary tissue sample and no staining of the HRS cells in 
the relapse tissue samples. Tissue samples of all other relapsed patients 
showed a strong staining. The percentage of cases with CD58 loss in relapsed 
HL patients was significantly higher than in the HL patients without relapse. 
These staining data showed that loss of CD58 on tumor cells is restricted to HL 
patients who do experience relapse (Table 1, Figure S3). Four of the six CD58 
negative cases, also stained negative for HLA class I, while the other 2 cases 
were not scorable, because of an insufficient amount of tissue. Due to the low 
number of CD58 negative cases, we cannot conclude whether loss of CD58 is 
specific for HLA class I negative cases, similar to the findings in DLBCL.11  
 
In conclusion, our results indicate that mutations in CD58 and loss of CD58 
expression are common in HL derived cell lines and that loss of CD58 



















Figure 1. CD58 expression in HL. (A) 
Schematic diagram of the CD58 gene 
and protein. Red arrows indicate the 
position of the stop gain mutation in DEV 
and the splice donor site mutation in 
KMH2. The red line indicates the 
homozygously deleted region in 
SUPHD1. The solid line represents the 
minimal deleted region and the dotted line 
represents the region for which loss is 
uncertain. The second allele most likely 
carriers a larger deletion. DEV and KMH2 
have homozygous mutations. (B) The bar 
graph below shows the qRT-PCR 
quantification of the relative CD58 mRNA 
expression (mean ± SD); (C) Flow 
cytometric analysis (mean fluorescence 
intensity, MFI ± SD) of membraneous 
CD58 in 7 HL cell lines using PE-labelled 
mouse anti-CD58 antibody (BD555921, 
BD Biosciences). (D) Protein expression 
as determined by Western blot using a 
polyclonal anti-CD58 antibody (1:1000; 
AF1689, R&D Systems, Minneapolis, 
USA) and GAPDH (1:20000, SC47724, 
Santa Cruz, Heidelberg, Germany). The 
molecular weight of the glycosylated 
CD58 protein is 45-100kDA depending on 
the extent of glycosylation on the 
extracellular domain. (E) Immunostaining 
of paraffin embedded HL tissue sections 
using a polyclonal antibody against CD58 
(1:80, AF1689, R&D Systems). 6 out of 
53 HL cases with relapse have 
diminished staining compared to HL 
cases without relapse. Shown are 
representative examples of positive and 
negative staining. Some cells in the 
microenvironment are positive as CD58 is 
expressed on B cells and T cells. Tonsil 
tissue was used as a positive control; the 
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Table 1. Distribution of age, follow up time, gender, histological subtype and 
CD58 staining in HL patients without relapse and HL patients with relapse.  
 
‡Mann Whitney U test, †Fisher’s exact test, *Chi square test. HL: Hodgkin lymphoma; 
cHL: classical Hodgkin lymphoma; NOS: cHL not otherwise specified; NLPHL: nodular 
lymphocyte predominant Hodgkin lymphoma 
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Supplementary Figure S1. CD58 mutations in HL cell lines. (A) Homozygous 
deletion of CD58 in SUPHD1. We inspect the coverage by using the IGV and run PCR 
with multiple primer set to validate the deletion. The arrows indicate the primer position. 
The solid line represent homozygously deleted region and dotted line represent the 
borders of the deletion for which loss is uncertain. (B) PCR validation for deletion in 
SUPHD1 revealed that the size of this single deletion is between 37.7kB (the distance 
between primer sets B and D) and 54.4kB (the distance between primer set A and E). 
(C) Validation of the stop gain mutation in DEV at the DNA and RNA level by PCR and 
Sanger-sequencing. (D) Validation of the splice donor site mutation in KMH2 at the DNA 









Supplementary Figure S2. CD58 expression in HL cell lines. (A) CD58 protein 
expression in HL cell lines as detected by FACS analysis. Gray-filled: blank; Blue line: 
isotype control; Red line: samples incubated with CD58 antibody. (B) CD58 
immunohistochemistry of HL cell lines. SUDHL4 cells were used as negative control. 
CD58 was absent in SUPHD1 with a homozygous deletion, DEV with stop gain mutation 
and KMH2 with splice donor site mutation. CD58 expression was detected in the other 







Supplementary Figure S3. Kaplan–Meier survival curve for relapse-free survival of 
Hodgkin lymphoma patients (n=96) who were CD58 positive (n=90) or CD58 
negative (n=6). CD58 negative patients had a significantly poorer relapse-free survival 












CD58 gene mutations in Hodgkin lymphoma 
67 
Supplementary Table S1. Distribution of age, gender, histological subtype and 
CD58 staining in HL patients without relapse and HL patients with relapse.  
 
*6 patients with both primary and relapse tissue. 4 patients have positive staining of 
HRS cells in both primary and relapse tissues samples, 1 patient showed no staining of 
HRS cells in both primary and relapse tissue samples and 1 patient showed a positive 
staining of HRS cells in the primary tissue sample and no staining of the HRS cells in 
the relapse tissue sample. 
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